Niall J. O’Reilly

Dr. Niall J. O’Reilly


Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 October 2021 in Drug Discovery Today
Verified
Journal Article
Closed access
Nasser AlhajjNasser Alhajj
Nasser Alhajj
NONiall J. O’Reilly
Niall J. O’Reilly
HCHelen Cathcart
Helen Cathcart

14 October 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
ABAyah Mohammad Burhan
Ayah Mohammad Burhan
BKButsabarat Klahan
Butsabarat Klahan
WCWayne Cummins
Wayne Cummins
VAVanessa Andrés-Guerrero
Vanessa Andrés-Guerrero
Mark ByrneMark Byrne
Mark Byrne
HHHelen Hughes
Helen Hughes
Posterior segment eye diseases (PSEDs) including age macular degeneration (AMD) and diabetic retinopathy (DR) are amongst the major causes of irreversible blindness worldwide. Due to the numerous barriers encountered, highly invasive intravitreal (IVT) injections represent the primary route to deliver drugs to the posterior eye tissues. Thus, the potential of a more patient friendly topical route has been widely investigated. Mucoadhesive formulations can decrease precorneal clearance while prolonging precorneal residence. Thus, they are expected to enhance the chances of adherence to corneal and conjunctival surfaces and as such, enable increased delivery to the posterior eye segment. Among the mucoadhesive polymers available, chitosan is the most widely explored due to its outstanding mucoadhesive characteristics. In this review, the major PSEDs, their treatments, barriers to topical delivery, and routes of topical drug absorption to the posterior eye are presented. To enable the successful design of mucoadhesive ophthalmic drug delivery systems (DDSs), an overview of mucoadhesion, its theory, characterization, and considerations for ocular mucoadhesion is given. Furthermore, chitosan-based DDs that have been explored to promote topical drug delivery to the posterior eye segment are reviewed. Finally, challenges of successful preclinical to clinical translation of these DDSs for posterior eye drug delivery are discussed.

18 June 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
SKSANGEETA KUMARI
SANGEETA KUMARI
MDMadhuri Dandamudi
Madhuri Dandamudi
SRSweta Rani
Sweta Rani
EBElke Behaeghel
Elke Behaeghel
GBGautam Behl
Gautam Behl
LFLaurence Fitzhenry
Laurence Fitzhenry
Dry eye disease (DED) or keratoconjunctivitis sicca is a chronic multifactorial disorder of the ocular surface caused by tear film dysfunction. Symptoms include dryness, irritation, discomfort and visual disturbance, and standard treatment includes the use of lubricants and topical steroids. Secondary inflammation plays a prominent role in the development and propagation of this debilitating condition. To address this we have investigated the pilot scale development of an innovative drug delivery system using a dexamethasone-encapsulated cholesterol-Labrafac™ lipophile nanostructured lipid carrier (NLC)-based ophthalmic formulation, which could be developed as an eye drop to treat DED and any associated acute exacerbations. After rapid screening of a range of laboratory scale pre-formulations, the chosen formulation was prepared at pilot scale with a particle size of 19.51 ± 0.5 nm, an encapsulation efficiency of 99.6 ± 0.5%, a PDI of 0.08, and an extended stability of 6 months at 4 °C. This potential ophthalmic formulation was observed to have high tolerability and internalization capacity for human corneal epithelial cells, with similar behavior demonstrated on ex vivo porcine cornea studies, suggesting suitable distribution on the ocular surface. Further, ELISA was used to study the impact of the pilot scale formulation on a range of inflammatory biomarkers. The most successful dexamethasone-loaded NLC showed a 5-fold reduction of TNF-α production over dexamethasone solution alone, with comparable results for MMP-9 and IL-6. The ease of formulation, scalability, performance and biomarker assays suggest that this NLC formulation could be a viable option for the topical treatment of DED.

1 June 2019 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
CDColin Dillon
Colin Dillon
HHHelen Hughes
Helen Hughes
NONiall J. O’Reilly
Niall J. O’Reilly
CAChris J. Allender
Chris J. Allender
DBDavid A. Barrow
David A. Barrow
PMPeter McLoughlin
Peter McLoughlin